FOR IMMEDIATE Release
AgMedica Bioscience Inc. Welcomes New Client Registrations Effective Immediately
CHATHAM, ONTARIO – August 1, 2018 – AgMedica Bioscience Inc. (“AGMEDICA” or the “Company”) welcomes new Clients to register and purchase dried medicinal cannabis products from its Riverview Cultivation Facility in Chatham, Ontario.
Regional Chatham-Kent employer and medical cannabis producer AgMedica Bioscience Inc. is pleased to announce that effective immediately, medical registrations are being accepted from patients seeking new health options and solutions to their unmet medical needs. “Working closely with healthcare professionals across many communities, AGMEDICA and our staff understand the patient treatment journey” said Bruce MacEachern, VP of Sales & Marketing at the company. He added, “We recently launched a patient-focused initiative entitled “Excellence in Cannabinoid Therapy Administration”, a collaborative effort that offers support, education and a standardized approach to healthcare providers as they explore new ways of providing their patients with cannabinoid options. This win-win approach will enable optimal patient care, support low risk and responsible cannabinoid use and foster an open and ongoing dialogue between patients and their trusted healthcare provider”.
On the journey to well-being, cannabinoid therapy holds promise for so many individuals, families and communities across Canada. Give our Client Care team a call today and consider the start of something new. Are you interested in becoming an AGMEDICA client? Talk to your healthcare professional first. Enrolling is then an easy 3-step process that can be done online, over the phone or by traditional mail. http://agmedica.ca/become-a-client/ Start your registration process today. Contact our Client Care team anytime at 1-844-569-2273 (844-5MY-CARE) or by email at ClientCare@AgMedica.ca
Let your journey begin today.
As a licensed producer and supplier of medicinal cannabis, AGMEDICA is dedicated to becoming a global leader in the production of cannabis and cannabis-derived products that improve our clients’ health and well-being. AGMEDICA’s investment in research and development is focused on scientific innovation that will have a positive impact on how cannabinoid therapies are approached, administered and maximized to obtain optimal heath outcomes. Phase I of our first innovative multi-tier cultivation facility in Chatham, Ontario has been completed with a total annual capacity of 6,000kg of medical-grade cannabis. Construction on Phase II of the Riverview Cultivation Facility is well under way and will bring the total annual capacity up to 26,500 kg. Expansion plans further to this will deliver close to 70,000kg total cannabis to market in the near term.
This press release contains forward-looking information based on current expectations. Statements about the anticipated facility capacity, among others, are forward-looking information. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. These risks and uncertainties include, but are not limited to, the Company’s ability to satisfy the conditions associated with its cultivation and sales license, the availability of further financing, consumer interest in its products, competition, regulation, operational and technological risks, and anticipated and unanticipated costs and delays. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law.
– 30 –
For further information:
Peter Van Mol
Chief Financial Officer